We examined the influence of sepsis on the expression and activity of the calpain and caspase systems in skeletal muscle. Sepsis was induced in rats by cecal ligation and puncture (CLP). Control rats were sham-operated. Calpain activity was determined by measuring the calcium-dependent hydrolysis of casein and by casein zymography. The activity of the endogenous calpain inhibitor calpastatin was measured by determining the inhibitory effect on calpain activity in muscle extracts. Protein levels of µ-and m-calpain and calpastatin were determined by Western blotting and calpastatin mRNA was measured by real-time PCR.
INTRODUCTION
Sepsis is associated with a catabolic response in skeletal muscle, mainly reflecting increased breakdown of myofibrillar proteins (19, 21) . Although ubiquitin-proteasomedependent proteolysis plays a prominent role in sepsis-induced muscle wasting, there is evidence that other mechanisms may be involved as well (22) , including lysosomal protein degradation (14) and tripeptidyl peptidase II activity (53).
An additional proteolytic pathway that has been implicated in the development of muscle wasting is the calpain system. The calpains constitute a family consisting of at least 14 members which may be ubiquitous enzymes, such as µ-and m-calpain, or tissue-specific proteins, such as the muscle specific calpain 3, also called p94 (17) . The regulation of calpain activity is complex. The most important activator of calpain is calcium but calpain activity may also be influenced by other factors. For example, certain phospholipids, in particular phosphatidylinositol, influence calpain activity by lowering tha calcium concentration needed for autolysis of µ-and m-calpain (10, 38, 39) . Other molecules as well have been proposed to regulate calpain activity by reducing the calcium requirements for activation, including isovalerylcarnitine (35) and an approximately 40-45 kDa endogenous "activator" present in skeletal muscle (36) . Recent studies suggest that µ-and m-calpain can be phosphorylated at multiple sites (9) and although the functional importance of calpain phosphorylation is not known at present, it is possible that µ-and m-calpain activity is influenced by phosphorylation of the enzymes (17) .
An important additional regulator of calpain activity is the endogenous inhibitor calpastatin (17) . Interestingly, calcium does not only activate calpains but also regulates the binding of calpastatin to calpain, resulting in inhibited calpain activity. In addition, calpain is autocatalyzed so that activated calpain degrades itself. Finally, activated calpain can degrade calpastatin, adding further complexity to the regulation of the calpain system. Support for a role of calpains in muscle wasting comes from previous studies in which we found that the mRNA expression of calpains was increased in muscle from septic rats (16, 50) . Reduced muscle calcium levels and inhibited protein breakdown after treatment with the calcium antagonist dantrolene provided further support for the concept that muscle protein breakdown in various catabolic conditions is at least in part regulated by a calciumdependent proteolytic mechanism (16) . Based on those and similar observations, we and others have proposed a model in which calpains provide an early, and perhaps rate-limiting step in muscle wasting, accounting for degradation of Z-band-associated proteins, in particular titin and α-actinin and resulting in release of mysoin and actin from the myofibrils (17, 19, 25, 41, 42, 50) . In this model, the released actin and myosin are subsequently ubiquitinated and degraded by the 26S proteasome (19) .
Although previous observations support a role of the calpain system in muscle wasting, the concept of calpain-mediated muscle proteolysis is controversial. One reason for this is that previous reports on calpain activity have been conflicting. For example, during sepsis, both increased (3) and unchanged (16) calpain activity in skeletal muscle have been reported.
One reason why previous results were apparently conflicting may be differences in experimental models as well as methods used for the measurement of calpain activity, including differences in the substrate used in the assay and the method used for extraction of muscle proteins. Another reason why previous reports have been inconsistent may be that attention was not being paid to the potential role of calpastatin and its inhibitory effect on calpain. This is important because when calpain activity is determined in tissue extracts by measuring the degradation of a substrate, results may be influenced by calpastatin bound to calpain. The importance of calpastatin was illustrated in a recent study in which muscle atrophy caused by unloading was reduced in transgenic mice overexpressing calpastatin in skeletal muscle (46). The influence of sepsis on calpastatin activity in skeletal muscle has not been reported.
While previous studies suggest that calpain activity may be involved in the release of myofilaments from the sarcomer during muscle wasting (17, 19, 25, 41, 42, 50) , a recent report by Du et al (15) challenged that concept and instead proposed that activation of caspase-3 may be the mechanism by which myofilaments are released from the myofibrils, at least in muscle atrophy caused by acute diabetes or chronic uremia. The influence of sepsis on caspase-3 expression and activity in skeletal muscle and the role of caspase-3 in sepsisinduced muscle wasting have not been reported.
The purpose of the present study was to test the hypothesis that muscle calpain activity is increased during sepsis and that this effect of sepsis is at least in part regulated by changes in calpastatin activity. In addition, we examined the potential role of caspase-3 in sepsisinduced muscle wasting by determining caspase-3 expression and activity in septic muscle as well as the effect of caspase-3 inhibitors on protein breakdown rates in muscle from septic rats.
MATERIALS AND METHODS

Experimental Animals
Sepsis was induced in male Sprague-Dawley rats (50-60g) by cecal ligation and puncture (CLP) as described in detail previously (16, 21, 44, 50) . Control rats underwent shamWei et al -6 operation, i.e., laparotomy and manipulation, but no ligation or puncture, of the cecum. Small rats were used because rats of this size possess extremity muscles that are thin enough to allow for in vitro incubation with maintained tissue oxygenation, energy levels and stable protein turnover rates (20) . All rats were resuscitated with 10 ml/100 g b.w. of saline administered subcutaneously on the back at the time of surgery in order to prevent the development of hypovolemia and septic shock. The animals had free access to drinking water but food was withheld after the surgical procedures in order to avoid the influence of differences in food intake between the septic and sham-operated rats on metabolic changes in muscle. Sixteen hours after sham-operation or CLP, extensor digitorum longus (EDL) and soleus muscles were harvested for determination of protein breakdown rates and calpain and caspase-3 expression and activity as described below. The septic model used here was used in several previous reports from our laboratory and results in a reproducible catabolic response in skeletal muscle and increased mRNA levels for multiple components of the ubiquitin-proteasome pathway and the calpain system (16, 21, 44, 50) . The experiments were approved by the Institutional Animal Care and Utilization Committee at the Beth Israel Deaconess Medical Center, Boston, MA.
Muscle Incubations
Sixteen hours after sham-operation or CLP, EDL and soleus muscles were dissected with intact tendons and incubated in vitro for 2h under physiological conditions as described previously (20, 21, 44) . The tendons of the muscles were fixed to stainless steel supporters and the muscles were maintained at resting length during incubation to provide optimal conditions with regards to energy levels and protein balance (1, 20) . Bilateral muscles from the same rats were incubated pair-wise in the absence or presence of calpain or caspase inhibitors as described in Results, followed by determination of protein breakdown rates and calpain activity. Protein breakdown rates were determined by measuring the net release of free tyrosine into the incubation medium using the fluorometric method described by Waalkes and Udenfriend (47) . Cycloheximide (0.5 mM) was added to the incubation medium in order to prevent reincorporation of tyrosine into proteins. Because tyrosine is not synthesized or metabolized in skeletal muscle, its net release during incubation provides an accurate estimate of total protein breakdown. dexamethasone and different protease inhibitors as indicated in Results. After treatment, the culture medium was transferred into a microcentrifuge tube containing 100 µl of bovine serum albumin (10 mg/ml) and TCA was added to a final concentration of 10% (w/v).
Cell
Samples were incubated at 4°C for 1 h followed by centrifugation for 5 min. The supernatant was used for determination of TCA-soluble radioactivity. The protein precipitates were dissolved with Tissue Solubilizer (Brinkman Instruments Inc., Westburg, NY). Cell monolayers were washed with ice-cold PBS and solubilized with 0.5 M NaOH containing 0.1% Triton X-100. Radioactivity in the cell monolayer and TCA soluble and insoluble fractions were measured using a Packard TRI-CARB 1600 TR liquid scintillation analyzer.
Protein degradation was expressed as the percentage protein degraded over the 24 h period and was calculated as 100 times the TCA-soluble radioactivity in the medium divided by the TCA-soluble plus the TCA-insoluble radioactivity in the medium plus the cell layer (i.e., myotube) radioactivity.
Calpain Activity
In order to test the effect of sepsis on muscle calpain activity, EDL and soleus muscles were harvested 16 h after CLP or sham-operation and immediately frozen in liquid nitrogen.
Muscles were then stored at -80 o C until analysis. In an additional experiment, the effect of calpeptin on calpain activity was tested in incubated muscles. In that experiment, muscles were rinsed, blotted dry and frozen in -80°C immediately after completion of the incubation.
For determination of calpain activity, frozen muscles were pulverized and homogenized in a buffer consisting of 20 mM Tris-HCl, pH 8.0, 5 mM EDTA-Tris, pH 7.2, 0.1% β-mercaptoethanol, 100 mg/l Trypsin inhibitor, 2.5 µM E-64 and 2 mM serine protease inhibitor PMSF. After centrifugation at 20,000 × g for 30 min at 4°C, protein concentration bovine serum albumin as standard.
Calpain activity in the supernatant was determined as described previously (43) conditions except that calcium was omitted and 100 mM EDTA was added to the assay.
Calpain activity was calculated as the difference between activity measured in the presence of 10 mM calcium and the activity measured in the absence of calcium and the presence of 100 mM EDTA. The assay, therefore, measured calcium-dependent degradation of casein.
Calpain activity was expressed as fluorogenic units (FU).
In additional experiments, calpain activity was assayed as described previously (16). The two major differences between that method and the method used here are: 1) Suc-Leu-Tyr-7-amino-4-methylcoumarin (SLY) was used as substrate in our previous study (16) whereas BODIPY-FL-casein was used here; 2) the techniques used for extraction of muscle proteins were different, one major difference being that protease inhibitors and the reducing agent mercaptoethanol were not included in the extraction buffer in our previous report (16) , whereas in the present study, multiple protease inhibitors and mercaptoethanol were included in the extraction buffer (see above). In one experiment, muscles were extracted as described previously (16) When calpain activity is measured in muscle extracts by determining the degradation of BODIPY-FL-casein or SLY, results may be influenced by the presence of calpastatin. In order to measure the activity of calpain independent of calpastatin, casein zymography was performed as described previously (12, 37) . In this assay, µ and m-calpain are separated by electrophoresis on a gel containing casein. Casein (0.02%, wt/vol) was copolymerized in a 10 % (wt/vol) acrylamide gel (pH 8.8). The casein gel was subjected to 30 min of preelectrophoresis (125V) with Tris-glycine buffer (pH 8.3) containing 1 mM EDTA and 0.1% 
Calpastatin Activity
Calpastatin activity was measured by determining the inhibitory effect of muscle extracts on calpain-mediated degradation of BODIPY-FL-casein as described in detail previously (28, 43) . The muscle extracts were heated at 100°C for 5 min before the assay in order to destroy calpain activity (28) . Purified µ-calpain (800 ng) from porcine erythrocytes (Calbiochem-Novabiochem Corp, San Diego, CA) and aliquots (50 µg protein) of muscle extract were added to microtiter plate wells and the volume was adjusted to 100 µl by adding Dilution Buffer (see above). The reaction was started by adding 100 µl of BODIPY-FLcasein (16 µg casein/ml) and the calpastatin activity (expressed as % inhibition of calpain activity) was calculated from the difference in calpain activity measured in the absence or presence of muscle extract (43) . In order to test the specificity of the calpastatin assay, a control experiment was performed in which an anti-calpastatin monoclonal antibody (Sigma, St Louis, MO) was added to the reaction as outlined in Results.
Caspase-3 Activity
Caspase-3 activity was determined as described in detail by Du et al (15) with minor modifications. In short, frozen muscles were pulverized and homogenized on ice in a buffer consisting of 100 mM HEPES (pH 7.5), 10 % sucrose, 0.1 % NP-40, 10 mM DTT, and protease inhibitor cocktail (Sigma, St. Louis, MO). Homogenates were subjected to three cycles of freeze-thaw before centrifugation at 18,000g for 30 min. Aliquots (20 µg protein)
were added to reaction buffer consisting of 100 mM HEPES (pH 7.5), 10 mM DTT and 10 % sucrose, and the mixture was preincubated for 30 min at 30°C with or without 50 µM of the cell-permeable caspase-3 inhibitor Ac-DEVD-FMK. The fluorogenic substrate Ac-DEVD-AMC (50 µM) was then added, and the reactions were performed at 30°C for 60 min.
Fluorescence was measured using excitation and emission wavelengths of 360 nm and 460 nm, respectively. Results were expressed as fluorogenic units (FU).
Western Blotting
Aliquots (50 µg of total cellular protein extracted as described above for the BODIPY-FL-casein method) of muscle extracts were loaded on 7 x 8 cm mini-gels (Millipore, Bedford, MA). SDS-PAGE was performed on 8% (for calpastatin) or 12.5% polyacrylamide gels (for all other proteins). The separated proteins were transferred electrophoretically using semi-dry transfer methodology onto nitrocellulose membranes (Millipore). The membranes were blocked with blocking buffer (5% nonfat dry milk, 50 mM Tris-HCl, pH 7. 
Real-time PCR
Caspase-3 and calpastatin mRNA levels were determined by real-time PCR performed as described in detail recently (34) . Total RNA was extracted by the acid-guanidinium thiocyanate-phenol-chloroform method using Tri Reagent (MRC Inc., Cincinnati, OH). The Amplification of 18S RNA was performed in the same reaction tubes as an internal standard with an alternatively labeled probe (VIC labeled probe) to distinguish its product from that derived from caspase-3 RNA. Caspase-3 and calpastatin mRNA concentrations were normalized to the 18S mRNA levels. Experiments were performed in triplicate for each standard and rat muscle sample.
Statistical analysis
Results are presented as means ± SEM. Statistical analysis was performed by using Student's t-test or ANOVA followed by Tukey's test as appropriate. Most experiments were repeated at least three times to provide evidence of reproducibility.
RESULTS
Sepsis increases muscle calpain activity secondary to decreased calpastatin activity
When calpain activity was determined by measuring the degradation of BODIPY-FLcasein 16h after sham-operation or CLP in rats, results showed that calpain activity was
increased by approximately 75% in EDL and 60% in soleus muscles of septic rats (Fig 1A) .
This result differs from a previous report from our laboratory in which we found no evidence of increased muscle calpain activity in septic rats (16) . In that study, the method used to measure calpain activity differed in two important aspects from the BODIPY-FL-casein method used here, i.e., the synthetic substrate SLY was used and extraction of muscle proteins was performed in a buffer lacking protease inhibitors and mercaptoethanol. In order to test whether one or both of these differences may account for the different results observed here (increased calpain activity in septic muscle) and in our previous study (unchanged calpain activity), two experiments were performed. First, calpain activity was determined using an identical method as described previously (16); calpain activity with this method did not show a difference between control and septic muscle (Fig 1B) , thus confirming our previous results (16) . Second, SLY was used in muscle extracts that had been generated in an identical manner to that used here in the BODIPY-FL-casein method, i.e., using a buffer containing protease inhibitors and mercaptoethanol. Employing this approach, results showed that calpain activity was increased in muscle from septic rats (Fig 1C) . Taken together, these results support the concept that sepsis increases calpain activity in skeletal muscle and suggest that the reason we were unable to demonstrate increased calpain activity in septic muscle in our previous report (16) reflected the fact that muscle proteins were extracted in buffer without protease inhibitors and mercaptoethanol (although the present experiments do not allow us to conclude whether the protease inhibitors or mercaptoethanol was most important for the present results, both groups of agents are important for maintaining the integrity and activity of the calpains).
Because the methods used here to determine calpain activity do not give specific information about µ-and m-calpain activity, we next measured calpain activity by zymography. The basal activity of µ-and m-calpain was different in EDL and soleus muscles with µ-calpain activity being higher in EDL and m-calpain activity being higher in soleus muscles (Fig. 2) . Importantly for the present study, µ-and m-calpain activities determined by zymography were not influenced by sepsis in either muscle when quantitations were performed by densitometry in multiple experiments (Fig 2 B and C) .
Although it is possible that the apparently conflicting results from the BODIPY-FLcasein assay and zymography reflected insufficient sensitivity of the zymography method compared to the BODIPY-FL-casein method, a more likely explanation is that results in the BODIPY-FL-casein assay are influenced by the presence of calpastatin whereas when zymography is performed, calpastatin is separated from the calpains (12, 37) . Thus, the increase in calpain activity noticed in the BODIPY-FL-casein assay may have been caused by reduced calpastatin activity. In order to test this mechanism, we next determined calpastatin activity in muscles from sham-operated and septic rats. Calpastatin activity was
reduced by approximately 60% in EDL and by approximately 40% in soleus muscles from septic rats (Fig 3) providing evidence for a potential mechanism of increased calpain activity determined in the BODIPY-FL-casein assay. In a control experiment, we tested the specificity of the calpastatin assay by adding an anti-calpastatin monoclonal antibody to the reaction. Addition of 0.4 µl of the antibody to the reaction (n=4) reduced the calpastatin activity by 100% in 3 assays and by 83% in one assay. In one experiment, two different amounts of anti-calpastatin antibody were added to the reaction, and the calpastatin activity (expressed as % inhibition of calpain activity) was 18 (no antibody added), 6 (0.2 µl antibody added), and 3 (0.4 µl antibody added), suggesting a dose-dependent inhibition of calpastatin activity by the antibody, further validating the calpastatin assay.
Calpastatin mRNA, but not protein levels, are reduced in septic muscle
In order to examine whether the reduced calpastatin activity in septic muscle was associated with changes in mRNA and protein expression of calpastatin, real-time PCR and Western blot analysis were performed. Calpastatin mRNA levels were reduced by 60-70% in both EDL and soleus muscles from septic rats (Fig 4) . Surprisingly, the decrease in calpastatin mRNA levels was not accompanied by reduced calpastatin protein levels (Fig 5) .
When Western blots of proteins from 10 control and 10 septic muscle extracts were quantitated by densitometry, calpastatin protein levels were almost identical in muscles from
sham-operated and septic rats (Fig 5 B) . Similar to a previous report from this laboratory (16), muscle µ-and m-calpain levels were also unaffected by sepsis (Fig 5 A, C , and D).
The calpain inhibitor calpeptin decreases muscle protein breakdown
In order to test whether calpain activity is involved in sepsis-induced muscle proteolysis, we treated muscles with the calpain inhibitor calpeptin (13) . When EDL muscles from septic rats were incubated in the presence of 100 µM calpeptin, both protein degradation rates and calpain activity were reduced (Fig 6) . Interestingly, calpain activity and protein degradation were inhibited by calpeptin in muscles from sham-operated rats as well, suggesting that basal muscle protein breakdown rates are also regulated by calpains.
Caspase-3 expression and activity are not increased in muscle from septic rats
Results in a recent study by Du et al (15) suggested that caspase-3, rather than calpains, may be involved in the regulation of muscle protein breakdown in muscle-wasting conditions. In order to test whether caspase-3 plays a role in the present model of muscle catabolism, the expression and activity of caspase-3 were determined in muscles from shamoperated and septic rats. Caspase-3 mRNA levels were not influenced by sepsis in EDL or soleus muscles (Fig 7A) . The 32kDa procaspase-3 is activated by caspase-9-regulated cleavage, resulting in 17kDa and 12kDa activated caspase-3 fragments (7, 15, 30, 32, 33) . No activated caspase-3 17kDa or 12kDa fragments were detected in EDL or soleus muscles from sham-operated or septic rats (Fig 7B) . The expression of caspase-3 was somewhat different in EDL and soleus muscles; thus, in soleus muscles, a cleaved 29kDa fragment was present.
Although this fragment may represent activated caspase-3 (4), there were no differences in the 32kDa and 29kDa caspase-3 levels between soleus muscles from sham-operated and septic rats (Fig. 7B) . Also, when caspase-3 activity was assessed by measuring hydrolysis of the fluorogenic substrate Ac-DEVD-AMC, there were no differences between muscles from sham-operated and septic rats (Fig. 7C) .
In order to further examine whether caspase-3 may be involved in sepsis-induced muscle proteolysis, EDL muscles from sham-operated and septic rats were incubated for 2h in the absence or presence of the caspase-3 inhibitor Ac-DEVD-CHO. We used the same concentration (10 µM) of Ac-DEVD-CHO that was used in the study by Du et al (15) in which the drug inhibited protein degradation in incubated epitrochlearis muscles from diabetic rats. Here, we found that Ac-DEVD-CHO did not reduce protein breakdown in EDL muscles from sham-operated or septic rats (Fig. 8) .
Protein degradation in cultured myotubes is reduced by inhibitors of calpain, but not caspase, activity
Because it is possible that the lack of effect of the caspase-3 inhibitor on protein degradation in incubated EDL muscles reflected insufficient length of treatment (2h), we next examined the effect of an extended period of treatment with the caspases-3 inhibitor Ac-DEVD-FMK. In this experiment, control and dexamethasone-treated L6 myotubes were exposed to Ac-DEVD-FMK for 24h. Dexamethasone-treated myotubes were used because in previous experiments, treatment of cultured L6 myotubes with dexamethasone resulted in a sepsis-like increase in proteasome-and calcium-dependent proteolysis (48) . Ac-DEVD-FMK did not reduce basal or dexamethasone-induced protein degradation in the myotubes ( Fig   9A) . Also, when the myotubes were treated for 24h with the caspase-9 inhibitor LEHD-CHO, basal and dexamethasone-induced protein degradation was unaffected (Fig. 9B) . In contrast, calpeptin blocked the dexamethasone-induced protein degradation in myotubes (Fig. 9C) lending further support to the concept that calpains regulate protein degradation in atrophying muscle.
DISCUSSION
In the present study, sepsis in rats resulted in increased calpain activity in skeletal muscle and this effect of sepsis reflected reduced calpastatin activity. The results are important because they reconcile, at least to some extent, previous apparently conflicting results from our laboratory with regards to muscle calpain activity during sepsis (16) . Thus, we found evidence that results may be influenced by the technique used to measure calpain activity. In particular, inclusion in the extraction buffer of agents that protect the calpains seems to be essential when calpain activity is measured. In addition, results are influenced by calpastatin activity when overall calpain activity is measured in muscle extracts as suggested by zymography that determines µ-and m-calpain activity individually and independent of calpastatin activity.
The present results support the concept that increased calpain activity may be an important mechanism of muscle wasting during sepsis and perhaps other catabolic conditions as well (16, 17, 50) . Additional support for a role of calpains in sepsis-induced muscle wasting was found in studies in which mRNA expression of µ-and m-calpain and p94 was increased in skeletal muscle of septic rats (16, 50) . In other studies, muscle calcium levels were increased in various muscle-wasting conditions (26, 50) and treatment of rats with the calcium antagonist dantrolene prevented the sepsis-induced increase in muscle calcium levels and protein breakdown rates (16, 24, 50, 52) . Taken together, those results suggest that sepsisinduced muscle proteolysis is at least in part regulated by calcium-activated proteases, possibly calpains. Because other reports provided evidence that the ubiquitin-proteasomedependent proteolytic pathway plays a central role in the development of muscle wasting (19, 44) despite the fact that the proteasome does not degrade intact myofibrils (27, 41, 42) , a model has been proposed in which muscle protein breakdown during sepsis and other catabolic conditions is initiated by calcium-calpain-mediated degradation of Z-bandassociated proteins, in turn resulting in the release of the myofilaments actin and myosin or fragments of these proteins (17, 19) . In this model, actin and myosin, released from the myofibrils, are subsequently ubiquitinated and degraded by the 26S proteasome. Recent studies suggest that the ubiquitin ligases atrogin-1 and MuRF1 may be particularly important for the regulation of ubiquitin-proteasome-dependent protein breakdown in various catabolic conditions (5,18,51). Thus, it is possible that calpain-dependent release of myofilaments is upstream of and at least in part may regulate the activation of atrogin-1 and MuRF1 although further studies are needed to determine the relationship between the activation of calpains and ubiquitin ligases in catabolic muscle.
It should be pointed out that in addition to sepsis, other catabolic conditions as well have been associated with increased calpain expression and activity. For example, a role of calpain-mediated proteolysis was reported in patients with acute quadriplegic myopathy (40) and in various muscular dystrophies (45) . Activation of calcium-dependent proteolysis (11) and increased mRNA expression of m-calpain (6) were observed in skeletal muscle of tumor bearing rats. When cultured myocytes were transfected with a dominant negative m-calpain, protein degradation was reduced by 30% and when calpastatin was overexpressed, protein degradation was reduced by 63% (25) . In the same study, inhibition of calpain activity also stabilized nebulin and it was concluded that calpains play a key role in the disassembly of sarcomeric proteins.
The present results, indicating an important role of reduced calpastatin activity for the activation of calpains in skeletal muscle during sepsis, support a recent report by Tidball and Spencer (46) . In that study, the authors generated transgenic mice that overexpressed calpastatin selectively in skeletal muscle. Overexpression of calpastatin reduced muscle atrophy by approximately 30% in their model of muscle wasting (unloading of hindlimb musculature for 10 days). Other reports as well support a role for changes in the balance between calpain and calpastatin in the regulation of muscle mass. For example, calciumdependent muscle proteolysis in tumor-bearing rats was found to reflect reduced calpastatin activity in a recent study by Costelli et al (11) . In other studies, calpain-dependent protein degradation in differentiating myoblasts reflected reduced calpastatin expression and increased calpain/calpastatin ratio (2).
The present results of reduced calpastatin activity in muscle from septic rats despite unchanged calpastatin protein levels, suggest that calpastatin activity may be regulated by mechanisms other than changes in the abundance of the peptide. Although it is well established that calpastatin-induced inhibition of calpain activity requires calcium-regulated binding of calpastatin to calpain, the exact mechanisms by which this binding is regulated and how calpain activity is inhibited are not fully understood at present. It is possible that binding of calcium to certain calpain domains results in conformational changes that increase the binding of calpastatin to calpain (31) . It has also been speculated that phosphorylation of calpains and calpastatin may influence the ability of calpastatin to bind to and inhibit the calpains (9, 17) . In a recent extensive review of the calpain/calpastatin system, Goll et al (17) pointed out that there is little information available on the regulation of the calpain/calpastatin interaction and that this regulation will likely be an area of considerable attention in the coming years. The results in the present study are important because they provide evidence that changes in calpstatain activity can occur without changes in calpastatin protein expression.
The present results also suggest that the regulation of calpastatin protein and mRNA expression is complex, at least in septic muscle. Thus, the unchanged calpastatin protein levels observed in muscles from septic rats, despite reduced calpastatin mRNA levels, suggest that the calpastatin protein levels were regulated by posttranscriptional mechanisms.
The unchanged calpastatin protein levels in the presence of reduced calpastatin mRNA levels may be consistent with increased translational efficiency, reduced degradation of calpastatin protein, or a combination of these changes. The exact mechanisms of unchanged calpastatin protein levels in muscle from septic rats, despite reduced expression of calpastatin mRNA, remains to be determined.
In contrast to the present and other reports, a recent study by Du et al (15) questioned the importance of calpains in the development of muscle atrophy. In that study, evidence was provided that increased caspase-3 activity may be the "upstream" mechanism by which myofilaments are released from the myofibrils followed by subsequent degradation by the Wei et al -23
ubiquitin-proteasome system. The conclusions in that study were based on experiments in which incubation of purified actomyosin or lysates from cultured L6 myotubes or rat psoas muscle with recombinant caspase-3 resulted in the production of a 14 kDa cleaved actin fragment. In subsequent experiments, the 14 kDa actin fragment was used as a marker of actin degradation in serum-deprived cultured L6 myotubes and in muscles from rats with acute diabetes or chronic uremia. When muscles from these rats were incubated in the presence of the caspase-3 inhibitor Ac-DEVD-CHO, the levels of the 14 kDa actin fragment were reduced, suggesting that caspase-3 was involved in the cleavage of actomyosin and actin. In addition, the authors reported data suggesting that caspase-3 activity was increased in gastrocnemius muscle of rats with acute diabetes. Unfortunately, calpain activity was not determined in the same muscles. In addition, the authors reported that tyrosine release from incubated epitrochlearis muscles from diabetic rats was reduced by approximately 13% by the caspase-3 inhibitor Ac-DEVD-CHO. This was a relatively modest reduction of protein degradation that did not prevent the diabetes-induced increase in muscle proteolysis. Thus, Although most reports are in agreement that the ubiquitin-proteasome system plays a central role in muscle wasting (19, 29) , the present results support the concept that other mechanisms may also be important (22) . The present study suggests that reduced calpastatin Results are means±SEM with n=8 in each group. *p<0.05 vs sham. 
